Biogen | BIIB - Equity Capital And Reserves


Biogen reported $18.85B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 6.76B 647M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 69.57B 3.24B Jun/2026
Sanofi EUR 73.14B 1.43B Mar/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026